Business Context and Reporting Period
This Form 8-K was filed by McKesson Corporation on December 26, 2012. The report details the entry into a material definitive agreement to secure financing for the proposed acquisition of PSS World Medical, Inc. It also announces the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, a key regulatory milestone for the transaction.
Key Financial Metrics and Debt Structure
The filing focuses on a new debt instrument rather than operational financial performance metrics such as revenue or profit.
- Bridge Loan Amount: $2.1 billion aggregate principal amount.
- Loan Type: One-year unsecured Senior Bridge Term Loan.
- Administrative Agent: Bank of America, N.A.
- Interest Rate Basis: Prime rate or London Interbank Offering Rate (LIBOR).
- Debt Covenant: Total debt to total capitalization ratio must not exceed 56.5%.
Material Changes and Transaction Purpose
The primary material change is the incurrence of the $2.1 billion bridge loan. The funds are designated for three specific purposes:
- Paying merger consideration for the acquisition of PSS World Medical.
- Repaying certain indebtedness of PSS World Medical and its subsidiaries outstanding prior to closing.
- Covering transaction costs associated with the acquisition.
The company expects to refinance all or part of this bridge loan with longer-term debt financing before the one-year term expires.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The bridge loan is a temporary financing solution intended to bridge the gap until permanent financing is secured. The transaction is contingent upon the closing of the acquisition and the availability of permanent financing.
Risks and Covenants: The loan agreement includes standard limitations on creating liens, engaging in certain mergers, and entering into swap contracts. It also mandates prepayments from net cash proceeds of equity issuances, asset sales, or property loss events outside the ordinary course of business.
Regulatory Status: The waiting period under the Hart-Scott-Rodino Act has been terminated early, allowing the transaction to proceed toward closing pending shareholder approval and other conditions.
Investor Verification Checklist
- Verify the final terms of the permanent financing intended to replace the $2.1 billion bridge loan.
- Review the definitive proxy statement for PSS World Medical shareholders for details on the merger consideration and voting requirements.
- Monitor the company's ability to maintain the 56.5% total debt to total capitalization ratio covenant.
- Confirm the closing date of the PSS World Medical acquisition.